Aller au contenu principal

 Articles scientifiques

Cancer Treatment and Research During the COVID-19 Pandemic: Experience of the First 6 Months.

Auteurs : de Las Heras B, Saini KS, Boyle F, Ades F, de Azambuja E, Bozovic-Spasojevic I, Romano M, Capelan M, Prasad R, Pattu P, Massard C, Portera C, Saini ML, Singh BP, Venkitaraman R, McNally R, Leone M, Grande E, Gupta S
Année : 2020
Journal : Oncol Ther
Volume : 8
Pages : 171-182

Management of cardiac disease in cancer patients throughout oncological treatment: ESMO consensus recommendations.

Auteurs : Curigliano G, Lenihan D, Fradley M, Ganatra S, Barac A, Blaes A, Herrmann J, Porter C, Lyon AR, Lancellotti P, Patel A, DeCara J, Mitchell J, Harrison E, Moslehi J, Witteles R, Calabro MG, Orecchia R, de Azambuja E, Zamorano JL, Krone R, Iakobishvili Z, Carver J, Armenian S, Ky B, Cardinale D, Cipolla CM, Dent S, Jordan K
Année : 2020
Journal : Ann Oncol
Volume : 31
Pages : 171-190

Trastuzumab emtansine (T-DM1)-associated cardiotoxicity: Pooled analysis in advanced HER2-positive breast cancer.

Auteurs : Pondé N, Ameye L, Lambertini M, Paesmans M, Piccart-Gebhart M, de Azambuja E
Année : 2020
Journal : Eur J Cancer
Volume : 126
Pages : 65-73

Incidence and Management of Diarrhea With Adjuvant Pertuzumab and Trastuzumab in Patients With Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer.

Auteurs : Bines J, Procter M, Restuccia E, Viale G, Zardavas D, Suter T, Arahmani A, van Dooren V, Baselga J, Clark E, Eng-Wong J, Gelber Rd, Piccart-Gebhart M, Mobus V, de Azambuja E
Année : 2020
Journal : Clin Breast Cancer
Volume : 20
Pages : 174-181.e3

Dose-dense adjuvant chemotherapy in HER2-positive early breast cancer patients before and after the introduction of trastuzumab: Exploratory analysis of the GIM2 trial.

Auteurs : Lambertini M, Poggio F, Bruzzone M, Conte B, Bighin C, de Azambuja E, Giuliano M, De Laurentiis M, Cognetti F, Fabi A, Bisagni G, Durando A, Turletti A, Urracci Y, Garrone O, Puglisi F, Montemurro F, Ceppi M, Del Mastro L
Année : 2020
Journal : Int J Cancer
Volume : 147
Pages : 160-169

Post-Mastectomy Radiation Therapy in Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer Patients: Analysis of the HERA Trial.

Auteurs : Abi Jaoude J, de Azambuja E, Makki M, Tamim H, Tfayli A, Geara F, Piccart-Gebhart M, Poortmans P, Zeidan YH
Année : 2020
Journal : Int J Radiat Oncol Biol Phys
Volume : 106
Pages : 503-510

A pooled analysis of the cardiac events in the trastuzumab adjuvant trials.

Auteurs : de Azambuja E, Ponde N, Procter M, Rastogi P, Cecchini RS, Lambertini M, Ballman K, Aspitia AM, Zardavas D, Roca L, Gelber Rd, Piccart-Gebhart M, Suter T
Année : 2020
Journal : Breast Cancer Res Treat
Volume : 179
Pages : 161-171

The impact of cyclin-dependent kinase 4 and 6 inhibitors (CDK4/6i) on the incidence of alopecia in patients with metastatic breast cancer (BC).

Auteurs : Eiger D, Wagner M, Pondé NF, Nogueira MS, Buisseret L, de Azambuja E
Année : 2020
Journal : Acta oncol (Stockholm)
Volume : 59
Pages : 723-725

Cardiotoxicity of trastuzumab given for 12 months compared to shorter treatment periods: a systematic review and meta-analysis of six clinical trials.

Auteurs : Eiger D, Franzoi MA, Pondé N, Brandão M, de Angelis C, Schmitt Nogueira M, de Hemptinne Q, de Azambuja E
Année : 2020
Journal : ESMO Open
Volume : 5

Early Modulation of Circulating MicroRNAs Levels in HER2-Positive Breast Cancer Patients Treated with Trastuzumab-Based Neoadjuvant Therapy.

Auteurs : Di Cosimo S, Appierto V, Pizzamiglio S, Silvestri M, Baselga J, Piccart-Gebhart M, Huober J, Izquierdo M, de la Pena L, Hilbers FS, de Azambuja E, Untch M, Pusztai L, Pritchard K, Nuciforo P, Vincent-Salomon A, Symmans F, Apolone G, De Braud FG, Iorio MV, Verderio P, Daidone MG
Année : 2020
Journal : Int J Mol Sci
Volume : 21

Differential Benefit of Adjuvant Docetaxel-Based Chemotherapy in Patients With Early Breast Cancer According to Baseline Body Mass Index.

Auteurs : Desmedt C, Fornili M, Clatot F, Demicheli R, De Bortoli D, Di Leo A, Viale G, de Azambuja E, Crown J, Francis PA, Sotiriou C, Piccart-Gebhart M, Biganzoli E
Année : 2020
Journal : J Clin Oncol
Volume : 38
Pages : 2883-2891

Repurposing anticancer drugs for COVID-19-induced inflammation, immune dysfunction, and coagulopathy.

Auteurs : Saini KS, Lanza C, Romano M, de Azambuja E, Cortes J, de Las Heras B, de Castro J, Lamba Saini M, Loibl S, Curigliano G, Twelves C, Leone M, Patnaik MM
Année : 2020
Journal : Br J Cancer
Volume : 123
Pages : 694-697

Metronomic chemotherapy combined with endocrine therapy: are we challenging some dogmas?

Auteurs : Caparica R, de Angelis C, Fêde Â, Werutsky G, de Azambuja E
Année : 2020
Journal : Expert Rev Anticancer Ther
Volume : 20
Pages : 563-573

HER2-positive advanced breast cancer treatment in 2020.

Auteurs : Cesca MG, Vian L, Cristóvão-Ferreira S, Pondé N, de Azambuja E
Année : 2020
Journal : Cancer Treat Rev
Volume : 88
Pages : 102033

Malignant bowel obstruction: effectiveness and safety of systemic chemotherapy.

Auteurs : Caparica R, Amorim L, Amaral P, Uratani L, Muniz D, Hendlisz A, de Azambuja E, Glasberg J, Takahashi TK, Filho EA, Canellas R, Saragiotto D, Sabbaga J, Mak M
Année : 2020
Journal : BMJ Support Palliat Care

Atezolizumab in metastatic triple-negative breast cancer: IMpassion130 and 131 trials - how to explain different results?

Auteurs : Franzoi MA, de Azambuja E
Année : 2020
Journal : ESMO Open
Volume : 5

CDK4/6 inhibition in HR-positive early breast cancer: are we putting all eggs in one basket?

Auteurs : Agostinetto E, Caparica R, de Azambuja E
Année : 2020
Journal : ESMO Open
Volume : 5

Prognostic role of distant disease-free interval from completion of adjuvant trastuzumab in HER2-positive early breast cancer: analysis from the ALTTO (BIG 2-06) trial.

Auteurs : Lambertini M, Agbor-Tarh D, Metzger-Filho O, Ponde NF, Poggio F, Hilbers FS, Korde LA, Chumsri S, Werner O, Del Mastro L, Caparica R, Moebus V, Moreno-Aspitia A, Piccart-Gebhart M, de Azambuja E
Année : 2020
Journal : ESMO Open
Volume : 5

Clinical management of first-line advanced triple-negative breast cancer patients

Auteurs : Rediti M, Punie K, de Azambuja E, Naert E, Taylor D, Duhoux FP, Denys H, Awada A, Wildiers H, Ignatiadis M
Année : 2020
Journal : Belgian J Medical Oncology
Volume : 14(7)
Pages : 333-338

Neoadjuvant letrozole plus taselisib versus letrozole plus placebo in postmenopausal women with oestrogen receptor-positive, HER2-negative, early-stage breast cancer (LORELEI): a multicentre, randomised, double-blind, placebo-controlled, phase 2 tria

Auteurs : Saura C, Hlauschek D, Oliveira M, Zardavas D, Jallitsch-Halper A, de la Peña L, Nuciforo P, Ballestrero A, Dubsky P, Lombard JM, Vuylsteke P, Castaneda CA, Colleoni M, Santos Borges G, Ciruelos E, Fornier M, Boer K, Bardia A, Wilson TR, Stout TJ, Hsu JY, Shi Y, Piccart-Gebhart M, Gnant M, Baselga J, de Azambuja E
Année : 2019
Journal : Lancet Oncol
Volume : 20
Pages : 1226-1238